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Group B streptococci (GBS) are a recently identified
cause of neonatal sepsis in Malawi. In Queen Elizabeth
Central Hospital, Blantyre, Malawi, during May 2004–June
2005, GBS were isolated from routine blood and cere-
brospinal fluid cultures from 57 infants. The incidence of
early (EOD) and late onset (LOD) invasive GBS disease
was 0.92 and 0.89 cases per 1,000 live births, respective-
ly. Sepsis (52%) was the most common manifestation of
EOD; meningitis (43%) and sepsis (36%) were the principal
manifestations of LOD. The case-fatality rate was 33%
overall (38% EOD, 29% LOD). Serotypes Ia and III were
responsible for 77% of disease. All isolates were suscepti-
ble to penicillin, but 21% were resistant to erythromycin.
The rate and manifestations of neonatal GBS disease in
Malawi are similar to those in industrialized countries, but
the case-fatality rate is higher than in industrialized coun-
tries. Effective locally relevant prevention strategies are
needed.
G
roup B streptococcus (GBS) has been a leading cause
of neonatal illness and death in many parts of the
world, especially industrialized countries, for several
decades (1–5). In contrast, until recently GBS was infre-
quently reported in the developing world. A World Health
Organization multicenter study of the bacterial etiology of
serious infections in young infants of <3 months of age
reported in 1999 that the “virtual absence of GBS was
striking” (6). Yet the prevalence of maternal carriage of
GBS in developing countries, including populations in
tropical Africa, is similar to that identified in populations
in the United States (7–9). Recent studies from Kenya
(10–12), South Africa (13,14), Zimbabwe (15), and
Malawi (16) suggest that GBS is emerging as an important
cause of neonatal sepsis in Africa. The largest of these
studies reported that 136 of 801 bacterial isolates from 784
Malawian neonates were GBS, which makes it the most
common cause of sepsis among neonates admitted to
Queen Elizabeth Central Hospital (QECH) in Blantyre
(16).
Prevention strategies such as chemoprophylaxis are
available for neonatal GBS but are difficult to apply in a
resource-limited setting (4,5). Vaccination is an attractive
option in this setting, and vaccines consisting of GBS cap-
sular polysaccharide conjugated to a tetanus toxoid carrier
protein have been under development (17–20). The vac-
cines are immunogenic in women but of unproven clinical
benefit. Important information to support future preventive
strategies includes estimate of rates of disease, timing of
disease initial manifestations; and for vaccine develop-
ment, description of serotype distribution in different pop-
ulations (5). Therefore, we set out to further characterize
GBS disease in Blantyre District in Malawi.
Methods
Study Setting
The study was conducted during 14 months from May
1, 2004, to June 30, 2005, at QECH in Blantyre District.
This district has the largest urban population in Malawi,
and much of the population lives in impoverished town-
ships. The predicted midyear population in 2005 was
1,070,173 (www.nso.malawi.net). This estimate is based
on projections from the 1998 national census. QECH is an
urban district hospital, which takes direct admissions and
referrals from surrounding district health centers. It is the
only major hospital providing free care in Blantyre. Birth
and death statistics for Blantyre for the study period were
obtained directly from QECH and the Blantyre District
Health Office.
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Study Population
Neonates (birth to 6 days of age) are normally admit-
ted directly to the neonatal nursery from the labor ward or
postnatal wards. Neonates may also be referred from sur-
rounding health centers in Blantyre District if problems
occur immediately after delivery. Young infants from birth
to 6 months of age (including those from birth to 90 days
of age) who were discharged well after delivery at QECH
or in peripheral health centers but in whom symptoms sug-
gestive of sepsis subsequently developed are normally
admitted to the pediatric ward. What proportion of infants
with sepsis in Blantyre is seen at healthcare facilities is not
known.
Guidelines exist for the investigation of sick children.
Cerebrospinal fluid (CSF) should be taken from all chil-
dren with suspected meningitis as well as blood cultures,
when there is evidence of sepsis (temperature >38°C) but
no signs to suggest localized disease. In practice this
means most neonates with nonspecific signs will have both
blood and CSF cultures taken before empirical antimicro-
bial agents are administered. Infants >1 month of age will
only have a blood culture taken if no clear focus of infec-
tion, e.g., pneumonia, is evident. Guidelines exist for the
use of intrapartum antimicrobial agents in febrile mothers
with suspected chorioamnionitis. If prolonged rupture of
membranes occurs and the neonate is admitted to the
neonatal nursery, antimicrobial agents are given empirical-
ly to the infant. No record or audit information is available
to assess adherence to the guidelines.
Culture of GBS from a blood or CSF sample from a
QECH pediatric inpatient <90 days of age was the entry
point to the study. Positive samples initiated a visit to the
patient and the collection of clinical and, later, outcome
data on the child. If a child had died with a positive GBS
culture, the death was attributed to GBS. No autopsy
results were available.
Most births take place at health facilities. Eighty-three
percent of women who live in an urban setting will deliv-
er at a health clinic or hospital (Malawi Demographic and
Health Survey preliminary report; www.nso.malawi.net).
HIV prevalence in mothers delivering at QECH was
30.2% from 2000 to 2004 (21)
Data Collection
Information on admissions to the neonatal nursery and
pediatric ward and the number of blood cultures taken was
obtained from ward admission books and laboratory
records. The clinical notes of patients from whom GBS
was isolated were reviewed. When no notes were available
(e.g., because of death or discharge of the child before
GBS was identified), the ward admission, ward round, and
books containing information about patients who died on
the ward were used to provide data. Information collected
included date of birth, age, sex, district of residence, birth-
weight, and gestational age at birth (defined by maternal
dates). If a child was born before 37 weeks’ gestation or
weighed <2.5 kg, he or she was classified as premature or
of low birthweight (LBW), respectively. Age at onset of
illness was used to classify the child’s condition as early
onset disease (EOD, defined as disease starting from birth
to 6 days after birth), or late onset disease (LOD, defined
as 7–90 days inclusive after birth). Outcome in hospital
was recorded as dead or alive at discharge. No attempt was
made to actively follow up the patients after discharge. 
Clinical Definitions
Disease type was categorized by using the following
criteria: 1) meningitis, pyogenic CSF from which GBS
was grown; 2) probable meningitis, no GBS isolated from
CSF but GBS isolated from blood and CSF findings con-
sistent with meningitis; 3) sepsis, GBS isolated from blood
with no clinical evidence of pneumonia, i.e., no increased
respiratory rate or chest retraction; 4) pneumonia, GBS
isolated from blood and definite clinical evidence of pneu-
monia, i.e., increased respiratory rate or chest retraction; 5)
unknown, GBS isolated from blood but insufficient infor-
mation to clinically categorize patient. The study was
approved by the College of Medicine Research and Ethics
Committee of the University of Malawi.
Laboratory Methods
Blood cultures are processed with a commercial blood
culturing system (BacTAlert, bioMérieux, Lyons, France).
CSF is processed by using standard methods. Positive
blood and CSF isolates are cultured on standard media by
using routine techniques. GBS was identified by its β-
hemolysis on blood agar (α-hemolytic and nonhemolytic
streptococci were not evaluated) and negative catalase
reaction. Serogrouping was conducted by using a latex
agglutination test (Pro-Lab Diagnostics, Wirral, UK).
Serotyping of the GBS isolates was performed with a com-
mercial serotyping kit according to the manufacturer’s
instructions (Statens Serum Institut, Copenhagen,
Denmark).
Disk-diffusion antimicrobial susceptibility testing was
performed according to the British Society for
Antimicrobial Chemotherapy guidelines on Isosensitest
agar (Oxoid Ltd, Basingstoke, UK) supplemented with 5%
sheep blood media (22). Antimicrobial agents tested
included penicillin, tetracycline, erythromycin, chloram-
phenicol, and ceftriaxone. All laboratory procedures were
internally quality controlled. The laboratory is enrolled in
the United Kingdom National External Quality
Assessment Service for Microbiology.Results
Clinical Characteristics
GBS was isolated from 57 infants in the 14-month
study period; of these, 41 isolates were from blood culture
only, 7 from both blood and CSF, and 9 from CSF alone.
With respect to the blood cultures, 3,159 infants were
admitted to the neonatal nursery during the study period;
blood cultures were drawn from 681 (22%) of these
patients, and 117 (17%) grew a clinically relevant isolate;
26 (22%) of these isolates were GBS. There were 4,297
children admitted to the pediatric ward; blood cultures
were drawn from 1,652 (38%) of these patients, and 173
(10%) grew a clinically relevant isolate; 22 (13%) of these
isolates were GBS. Admission numbers and blood cultures
could not be accurately analyzed by age of the patient for
the pediatric ward. Of the 57 patients, 19 died, 35 were
discharged, and the outcome of 3 patients was not ascer-
tained. The overall case-fatality rate was 33%. The Table
contains a summary of the major clinical findings.
Seven (16%) of 45 infants with known gestational age
were preterm, and 10 (20%) of 51 infants with known
birthweight had LBW. Whether disease was early or late
onset was not associated with these variables. Meningitis
was more common among infants with LOD than those
with EOD (Table), but the difference did not reach statisti-
cal significance (χ2 = 3.4, p = 0.07).
Of the isolates, 29 (51%) were from infants with
EOD, and the median age of patients with initial symptoms
was 1 day. The case-fatality rate was 38% for EOD.
Twenty-eight isolates (49%) were from infants with LOD.
The median age of LOD was 14 days (range 7–42 days),
and the case-fatality rate was 29%.
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Of the 57 patients in whom GBS was identified, 52
had isolates available for serotyping. GBS were isolated
from both blood and CSF in 7 cases, but both isolates were
available for typing in only 4 cases; in all of these cases,
the serotypes were the same. Thus, only 1 isolate per infant
was included in the analysis. No GBS isolates were nonty-
peable. Serotype III (56%) and serotype Ia (21%) were the
most frequently identified serotypes; they constituted 77%
of both EOD and LOD (Figure).
Disease manifestations by serotype are shown in the
Table. No discernible differences were found in EOD or
LOD, clinical manifestations, or outcome by serotype. Of
the 51 infants for whom a birthweight was recorded,
serotype Ia caused more disease among LBW babies than
among those of normal birthweight, but the trend was not
significant (40% vs. 17%, respectively, χ2 = 3.1, p = 0.08).
Disease due to serotype III was less common in those of
LBW (30% vs. 68%, respectively, χ2 = 4.3, p = 0.04).
All GBS isolates were susceptible to penicillin, and all
but 2 isolates were resistant to tetracycline (Table).
Serotype and antimicrobial susceptibility were not statisti-
cally associated.
Incidence Rate Estimates
During the study period, May 1, 2004–June 30, 2005,
a total of 31,458 live births were recorded in Blantyre
District; a birth rate of 25.2/1,000 population. Of these
births, 12,064 took place in QECH and 19,394 took place
in district health centers. Therefore, the overall GBS dis-
ease incidence was 1.8/1,000 live births. The incidence of
EOD was 0.92/1,000 live births, and the incidence of LOD
was 0.89/1,000 live births. During the study period, 711
neonatal deaths (23% of all admissions) occurred in the
neonatal nursery. A further 353 deaths (8% of all admis-
sions) occurred in the pediatric ward, but these deaths
could not be analyzed by age. GBS was implicated as a
cause of death in 11 (2%) of the deaths in the neonatal
nursery and in 8 (2%) of all the deaths in the pediatric
ward.
Discussion
This study adds to the growing evidence that GBS is
an important cause of infectious neonatal illness and death
in Africa. The incidence and outcome of disease support a
more active approach for its prevention.
These results provide a benchmark for future studies
with what we believe to be reasonable minimum estimates
of disease incidence, despite measurement limitations in
both our denominator and numerator figures. The recorded
number of live births during the study period for Blantyre
District is almost certainly an underestimate of the actual
number. Our calculated birth rate of 25/1,000 population is
low for an African urban population. A recent household
demographic survey estimated the birth rate in urban
Malawi at 37/1,000 (www.nso.malawi.net); thus, our live
birth numbers may be underrecorded by as much as one
third.
Set against this background, case-ascertainment of
GBS was also suboptimal. Surveillance for GBS was pas-
sive. Only 1 in 5 infants admitted to the neonatal nursery
and 2 in 5 admitted to the pediatric ward had a blood cul-
ture performed as part of the investigation of their illness.
Although guidelines for assessing sick neonates exist, no
audit of their implementation has been undertaken in the
hospital, and shortages of syringes, needles, blood tubes,
and staff are commonplace. The relatively low numbers of
EOD to LOD and the high number of deaths may also be
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Figure. Pie chart showing serotype distribution of group B strepto-
coccus isolates from infants with early (A) or late onset (B) dis-
ease. *Two isolates from early onset disease and 3 from late onset
disease were not available for typing.in part explained by selective sampling of the sicker chil-
dren, rather than a fundamental difference in disease
pathology in Malawi.
What proportion of sick neonates was seen in QECH
and how many died before they received any form of
healthcare are unclear. Using data from the household
demographic survey (a birth rate of 37/1,000 population
and a reported neonatal death rate of 27/1,000 births
[www.nso.malawi.net]) and the projected population size
for Blantyre (www.nso.malawi.net/data_on_line/demo
graphy/projections/pop/bt_rural.htm and bt_city.htm), we
would have expected ≈1,250 neonatal deaths in Blantyre
during the study period. The 711 recorded deaths in the
neonatal nursery and a proportion of the 353 deaths on the
pediatric ward suggest that most neonatal deaths in
Blantyre occur in QECH, but a sizeable proportion do not.
We believe our results are likely to underestimate rates of
GBS disease with the extent of lack of case recognition
being greater than the underreporting of births.
The overall rate of GBS disease in Blantyre is higher
than the overall rates of 0.6–0.9/1,000 live births reported
from Western Europe (3,23,24). However, the rate of EOD
is lower than that documented in the United States and
Australia before the use of intrapartum prophylaxis,
1.7–2.0/1,000 live births, (1,2). Little information is avail-
able about rates of invasive disease in Africa for compari-
son. A study from the principal public-funded hospital in
Johannesburg, South Africa, reported an EOD rate of
2.06/1,000 live births (14). That study used similar meth-
ods to our own for the rate calculations, although the cal-
culated crude birth rate from the figures reported
(≈18/1,000 population) suggests underreporting of births
for the denominator and overall rates that may be similar
to those in Blantyre. Another study from Johannesburg
reported an EOD incidence rate of 1.16/1,000 live births
(13) although the sociodemographic background of the
population under study here is less clear. In a rural setting
in East Africa, GBS bacteremia occurred at a rate of
0.66/1,000 births in neonates (10), which suggests that the
extent of disease is greater in urban or southern Africa at
this time.
The rates of EOD and LOD in this study were similar.
In other settings, EOD is much more frequent than LOD
when prophylaxis is not available. Our findings may in
part be explained by selective sampling, but other factors
may have also contributed. Some cases of EOD may have
been prevented by empirical administration of antimicro-
bial agents, in keeping with the guidelines for chorioam-
nionitis and prolonged rupture of membranes, although we
have no information as to the extent of this practice.
Another possibility is that some of our LOD was in fact
EOD because the patients had symptoms of illness for
some time before seeking healthcare.
We found serotypes III and Ia to be the predominant
serotypes, comprising 77% of cases; serotypes II, Ib, and
V constituted the rest. This breakdown is similar to that in
the single other report from Africa to date that assessed
serotypes. That study, from South Africa, showed that in
infants with EOD serotype III isolates caused 49.2% of
disease and, together with serotype Ia isolates, caused
78.9% of disease (14). Studies from the industrialized
world, in Finland (25) and Sweden (26), found a similar
predominance of III and Ia. We found only 1 case of
serotype V disease in contrast with findings from more
recent studies from England (3), Sweden (27), and the
United States (28), where serotype V is increasingly recog-
nized as a cause of invasive disease. Serotype V was the
predominant serotype, however, in a large Gambian study
of maternal colonization (8) and was frequently identified
in a similar Zimbabwean study (29). Neonatal disease was
uncommon in the Gambian study, which suggests that fac-
tors other than bacterial serotype are required for disease to
occur.
We found the rate of LOD, 0.89/1,000 live births, was
slightly less than that of 1/1,000 live births reported in the
South African study (14), although serotypes III and Ia
were similarly responsible for most cases. We did not,
however, define an association between serotype and tim-
ing of disease. These findings differ from reports from the
industrialized world and from South Africa, where
serotype III is clearly associated with LOD. This finding
may also be a consequence of a case-finding bias with the
youngest and sickest being more selectively investigated.
The median age of patients with LOD in our study was 14
days; only 1 case occurred after the child was 28 days of
age. This finding could be because hospitalized infants
>28 days of age are less likely to have a blood culture
taken if they have localized signs of sepsis, e.g., pneumo-
nia. A more systematic and definitive approach to sam-
pling will be required to further assess this finding.
Disease manifestations were similar to those in other
studies, apart from a higher proportion of EOD (31%)
manifesting as meningitis. Other studies have reported
6%–10% of EOD as meningitis (2,3). The high rate could
be explained by preferential sampling of the sickest infants
in circumstances of limited resources. We found that reli-
ably differentiating sepsis from pneumonia was problem-
atic, again, as a result of the lack of investigative facilities;
thus, we may have underdiagnosed cases of pneumonia.
The case-fatality rate in this case-series resembles that
seen in the United States in the 1970s, when the case-fatal-
ity rate was >50% (30,31). Our case-fatality rate is much
higher than that more recently recorded in Europe
(8%–9%) (3,25,32), the United States (4%–6%) (2), or
South Africa (19.8% for EOD and 13.6% for LOD) (14).
This finding likely reflects the difficulties of managing
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these infants with limited resources, lack of intensive care
facilities, and late seeking of healthcare for some infants,
and possibly coexistent illness such as HIV.
We do not have any information on HIV status of
mothers or children in our study. Speculation that the
emergence of GBS as a pathogen in southern and eastern
Africa is related to HIV infection is tempting. HIV-infect-
ed adults have defects in the humoral immune responses to
polysaccharide antigens, best recognized in the case of
pneumococci (33). GBS capsular polysaccharides are sim-
ilar to pneumococcal capsular polysaccharides, and sero-
logic cross-reactivity is recognized (34). Thus,
HIV-infected women might carry more GBS and might
transfer less transplacental protection. Further research in
this area is required.
We found all isolates were susceptible to the β- lactam
antimicrobial drugs and that most (96%) were resistant to
tetracycline, as would be expected. However, 21% of iso-
lates were resistant to erythromycin, which is a higher pro-
portion than that reported from the United Kingdom (4%
erythromycin resistant) (3) but similar to that reported
from France (21.4%) (35), the United States (20%) (36),
and Zimbabwe (14%) (37). Chemoprophylaxis with ante-
natal azithromycin is under evaluation as a means to
improve pregnancy outcome in Malawi, primarily by
reducing chorioamnionitis (including that caused by GBS)
and possibly malaria. Were this treatment to become avail-
able, this higher rate of resistance to macrolides may limit
the value of this approach in reducing GBS-associated
pathology and could limit options for intrapartum antimi-
crobial prophylaxis for penicillin-allergic patients. 
From our data, interventions to prevent GBS disease
appear warranted. Chemoprophylaxis has been successful
in reducing rates of EOD in many countries (2,5). An intra-
partum screening–based approach for prophylaxis would
not be feasible because microbiology facilities are lacking
in both QECH and the surrounding districts. Risk-based
prophylaxis could be considered. However, only a small
proportion of these infants were of LBW (10), and of these
only 7 were noted to be premature. We had insufficient
information about the obstetric histories to examine risk
factors such as prolonged rupture of membranes, maternal
fever, and prolonged labor. Vaginal disinfection with
microbicides during labor has been considered in develop-
ing countries (38). In Malawi, the use of chlorhexidine
wipes significantly reduced neonatal and maternal
sepsis–related illness and death at QECH in a study in
which the primary aim was to reduce perinatal HIV trans-
mission (39). This approach is likely to be less effective
when a high proportion of deliveries take place without
healthcare supervision, and this fact may in part explain
the failure of this technique to become routine practice.
A vaccine-based strategy would be particularly suited
for use in the developing world, where maternal immu-
nization with tetanus toxoid is a safe and valuable part of
routine antenatal care (40). However, the impetus to devel-
op these vaccines has diminished because of the success of
chemoprophylaxis in industrialized countries. Vaccination
would appear to offer the widest coverage for a successful
intervention and would likely offer protection from both
EOD and LOD. Our study suggests that an efficacious 2-
valent vaccine aimed at serotypes Ia and III could prevent
>75% of invasive disease due to GBS in Malawian infants.
In summary, we have demonstrated a pattern of
neonatal GBS disease similar in scale and serotype distri-
bution to reports from the industrialized world but with a
significantly worse outcome. We suggest that the effective-
ness of vaginal disinfection should be further assessed and
that the currently stalled vaccine development programs of
recent years be restarted with a clear intention of assessing
their role in the developing world.
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